Lyell Immunopharma (NASDAQ:LYEL) Stock: Insider Venture Fund Xiii L.P. Arch Purchases 2,321,262 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) major shareholder Venture Fund Xiii L.P. Arch bought 2,321,262 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were purchased at an average cost of $10.77 per share, with a total value of $24,999,991.74. Following the transaction, the insider directly owned 3,747,790 shares in the company, valued at approximately $40,363,698.30. This trade represents a 162.72% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL traded down $0.43 during midday trading on Thursday, reaching $15.00. The stock had a trading volume of 657,433 shares, compared to its average volume of 139,964. The firm has a market cap of $367.50 million, a price-to-earnings ratio of -1.17 and a beta of -0.04. Lyell Immunopharma, Inc. has a twelve month low of $7.20 and a twelve month high of $45.00. The company’s 50 day moving average price is $10.85 and its 200 day moving average price is $16.73.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.20. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The company had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.01 million. Equities analysts forecast that Lyell Immunopharma, Inc. will post -7.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LYEL has been the subject of a number of research reports. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. B. Riley Financial assumed coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a report on Friday, August 14th. Finally, Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, October 25th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.86.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. boosted its stake in shares of Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after buying an additional 264,928 shares during the last quarter. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma during the second quarter valued at approximately $4,744,643. Renaissance Technologies LLC increased its position in shares of Lyell Immunopharma by 194.8% during the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after acquiring an additional 76,921 shares during the last quarter. Velan Capital Investment Management LP lifted its holdings in Lyell Immunopharma by 2.9% during the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock worth $1,475,000 after acquiring an additional 3,000 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Lyell Immunopharma during the first quarter worth $959,000. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma News Summary

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Updated ronde-cel results showed high response rates in patients with relapsed or refractory large B-cell lymphoma: in the pivotal 3L+ trial, the overall response rate was 91% and the complete response rate was 77%; results in the 2L cohort were 95% and 76%, respectively. Severe cytokine release syndrome was not observed in either group. The data will be presented at the ASH meeting and support interest in the therapy’s potential. Article: Positive updated ronde-cel data
• Positive Sentiment: Lyell secured an approximately $80 million private placement to fund ronde-cel development toward a planned biologics license application (BLA). Needham also gave the shares a “Buy” rating, while a Seeking Alpha article cited the clinical progress and financing in an upgrade to “Buy.” Article: $80 million private placement Article: Needham Buy rating Article: Seeking Alpha upgrade
• Neutral Sentiment: Third-quarter loss per share was $1.86, narrower than analysts’ expected $2.06 loss, but revenue was zero. The earnings beat is modestly favorable, though the results underscore Lyell’s pre-commercial stage and ongoing losses. Article: Third-quarter results
• Negative Sentiment: The private placement involves selling common stock, which can dilute existing shareholders. Investors will also be weighing clinical promise against the remaining development and regulatory risks before ronde-cel can reach the market.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.